Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: 2006 + 0.36 + web  Related to the article below (Last Update: 8/4/2008)

ADP Reports Fiscal 2008 Results; Provides Fiscal 2009 Guidance
Trading Markets (press release), CA - Jul 31, 2008
ADP's news releases, current financial information, SEC filings and Investor Relations presentations are accessible at the same Web site. ...ADP
Waddell & Reed Financial, Inc. Reports Second Quarter Results
MarketWatch - Jul 29, 2008
This has resulted in steady improvements to net flows every year since 2006. It is notable and gratifying that this progress has continued through the ...WDR
Dominion Announces Second-Quarter 2008 Earnings
Earthtimes (press release), UK - Jul 31, 2008
4) Refer to schedules 2 and 3 for details related to items excluded from operating earnings, or find "GAAP Reconciliation" on Dominion's Web site at ...D
Highwoods Properties Reports Second Quarter 2008 Results
Trading Markets (press release), CA - Jul 29, 2008
A live listen-only Web cast can be accessed through the Company's web site at www.highwoods.com under the "Investor Relations" section. ...HIW

WELT ONLINE
Carolina Bank Holdings, Inc. Announces Improved Asset Quality and ...
MarketWatch - Jul 16, 2008
Further information is available on the Company's web site: www.carolinabank.com. This press release contains forward-looking statements regarding future ...
Huntington Bancshares Reports 2008 Second Quarter Net Income of ... FOXBusiness
all 467 news articles »  CLBH - HBAN - FCMC
InvestSource, Inc.: Ernest G. Sorochan, P. Eng. Appointed as ...
Trading Markets (press release), CA - Jul 21, 2008
The Standard & Poor's 500 index rose 0.36, or 0.03 percent, to 1260.68, and the technology-focused Nasdaq composite index dropped 29.52, or 1.28 percent, ...FRE - TE - ZION
Alliance Data Announces Second Quarter Results
Earthtimes (press release), UK - Jul 16, 2008
In addition, during the quarter we signed a new client, PeachDirect, which is a fast growing web and catalog retailer of luxury merchandise. ...ADS
Emera Reports Q2 2008 Earnings of $42.9 million
Canada NewsWire (press release), Canada - Aug 1, 2008
Visit Emera on the web at www.emera.com. Management's Discussion & Analysis As at August 1, 2008 Management's Discussion and Analysis ("MD&A") provides a ...TSE:EMA
Sovereign Bancorp, Inc. Announces Second Quarter 2008 Results
MSN Money - Jul 23, 2008
Investors, analysts and other interested parties will have the opportunity to listen to a live web-cast of Sovereign's Second Quarter 2008 earnings call on ...SOV
George Weston Limited - Quarterly Report to Shareholders
Canada NewsWire (press release), Canada - Jul 29, 2008
During 2006, Weston Foods approved a restructuring plan to downsize its fresh-baked goods facility in Bay Shore, New York. The plan, which is now complete, ...TSE:WN - TSE:L - KDQ:032790
Source: Google News

Utilizing Search Intent in Topic Ontology-Based User Profile for Web Mining -
X Zhou, ST Wu, Y Li, Y Xu, RYK Lau, PD Bruza - … of the 2006 IEEE/WIC/ACM International Conference on Web …, 2006 - doi.ieeecomputersociety.org
... IEEE/WIC/ACM International Conference on Web Intelligence, Beijin ... on Active Media
Technology, Brisbane, Australia, 2006. 0.33 0.34 0.35 0.36 0.37 0.38 0.39 0.4 ...

WESTON (GEORGE) LIMITED
F Data, B Sheet, S Record - doi.wiley.com
... 3/13/2006 3/15/2006 4/1/2006 0.36Q 5 ... Going forward, Co.'s outlook for 2006 is for
continued growth ... East, Toronto, M4T 2S7 Telephone: 416-922-2500 Web Site: www ...

[CITATION] Web Mining System for Mobile-Phone Marketing
VII Chapter - Business Applications and Computational Intelligence, 2006 - Idea Group Pub.
-

Finding near-duplicate web pages: a large-scale evaluation of algorithms -
M Henzinger - Proceedings of the 29th annual international ACM SIGIR …, 2006 - portal.acm.org
... Copyright 2006 ACM 1-59593-369-7/06/0008 ... following definition for a correct
near-duplicate: Two web pages are ... 0.48 0.1 (0.04) B-sim 4 240 0.55 0.36 0.09 (0.05 ...

… for Pediatric Gastroenterology, Hepatology, and Nutrition Annual Meeting, October 19-22, 2006, …
M Feist, J Fitzgerald, J Rushton, J Croffie, S … - Journal of Pediatric Gastroenterology & Nutrition, 2006 - jpgn.org
... Annual Meeting October 19Y22, 2006 Orlando, Florida POSTER SESSION I THURSDAY,
OCTOBER 19, 2006 5 PM Y 7 PM Cellular/Molecular Biology ...

Interpreting Results from Large Scale Automatic Evaluation of Web Accessibility -
C B?hler, H Heck, O Perlick, A Nietzio, N Ullveit … - Computers Helping People with Special Needs, 2006 - Springer
... c Springer-Verlag Berlin Heidelberg 2006 ... to compare the results from automatic web
accessibility assessment ... 0.15 0.15 0.10 0.10 0.15 0.15 0.36 0.36 User rating ...

[PDF] The role of ciliates within the microbial food web in the eutrophicated part of Ka?tela Bay (Middle … -
N Bojanic, M ?olic, N Krstulovic, S ?estanovic, … - Scientia Marina, 2006 - Consejo Superior de Investigaciones Cientificas
... RELATIONSHIPS WITHIN MICROBIAL FOOD WEB ? 435 ... connection between these parameters
was less pronounced (r 2 =0.36, p<0.001 ... MAR., 70(3), September 2006, 431-442 ...
-

Web Search Engine as a Bee Hive -
P Navrat, M Kovacik - … of the 2006 IEEE/WIC/ACM International Conference on Web …, 2006 - doi.ieeecomputersociety.org
... 0.65], source54[0.56], source98[0.54], source43[0.36], source11[0.33 ... Proceedings
of the 2006 IEEE/WIC/ACM International Conference on Web Intelligence (WI ...

Relationship between web links and trade -
R Baeza-Yates, C Castillo - … of the 15th international conference on World Wide Web, 2006 - portal.acm.org
... WWW 2006, May 23?26, 2006, Edinburgh, Scotland. ... Table 2: Comparison of cross-
similarities between Web links and exports. ... Chile 0.36 0.43 0.45 0.48 0.50 ...

[PDF] Assigning and Visualizing Music Genres by Web-based Co-Occurrence Analysis -
M Schedl, T Pohle, P Knees, G Widmer - Proceedings of the Seventh International Conference on Music …, 2006 - cp.jku.at
... c 2006 University of Victoria ... For Punk Rock, this correlation equals 0.36. ... We have
presented a web-based artist-to-genre classification approach with ...

Source: Google Scholar
 
 

Gleevec's Potency Against Chronic Myeloid Leukemia Shown By 5-Year Study

Article Date: 11 Dec 2006 - 6:00am (PST)
In a study of patients with chronic myeloid leukemia, some 95 percent have survived the cancer after five years due to treatment with Gleevec, according to results published this week in the New England Journal of Medicine.

Howard Hughes Medical Institute investigator Brian Druker, who led the five-year study, said the findings demonstrate Gleevec's effectiveness against the formerly fatal disease. He noted that the study's results emphasize the value of the new approach to developing cancer drugs that target the specific genetic malfunctions that drive cancer.

Druker, who is at the Oregon Health & Science University Cancer Institute, led an international group of 31 co-authors who published their findings in the December 7, 2006, New England Journal of Medicine.

Druker also led the original clinical development of Gleevec, which inhibits a biological switch called a tyrosine kinase that is abnormally activated in CML. This activation, triggered by an abnormal breakage and rearrangement of a chromosome, drives uncontrolled proliferation of white blood cells. CML is a relatively rare disorder that affects about 5,000 people a year in the United States. Gleevec, marketed by Novartis, is the trade name under which the drug imatinib is sold.

Article continues below and (thank you)
 
The five-year study followed 553 patients, all of whom were receiving Gleevec as their primary therapy. The study had begun as a comparative study of patients given Gleevec or the previous standard treatment, interferon alfa plus cytarabine. However, the superiority of Gleevec led the researchers to change the study into a long-term assessment of Gleevec's efficacy. The major finding of the study was that only five percent of the patients died from CML during the five-year period, with 11 percent dying from all causes.

The report shows that the drug produced few significant side effects. "The issue of side effects is an important one, because patients with CML need to remain on Gleevec long-term," said Druker. "We found that the incidence of side effects was quite low, and most of the serious side effects occurred in the first year or two of starting therapy." One particular worry, he said, was whether the drug would damage the heart. "We found, however, that only one patient developed heart failure that was thought to be related to the drug, so the risk is incredibly low."

The researchers also found that patients did respond less to Gleevec therapy if they were in a high-risk category due to such factors as an enlarged spleen or a high percentage of immature white cells in their blood. "Even high-risk patients have close to a 70 percent chance of getting to what we call a complete cytogenetic response, which is an optimal response to the drug," said Druker. "That is still six or seven times better than they ever could have hoped for with the previous standard therapy. So, even for high-risk patients, the likelihood of responding is quite high." A cytogenetic response is the measure of the reversion of white blood cells to normal function.

"And more importantly, we found that if a patient achieves a complete cytogenetic response, the risk of relapse is the same whether the patient was at low, medium, or high risk when diagnosed," said Druker. "This finding that Gleevec response trumps the patient's features at diagnosis is critically important, because with the previous standard treatment such a response was not protective from relapse. So, the Gleevec response is, indeed, protective," he said.

Druker said that Gleevec's long-term efficacy also offers a benchmark for comparative testing of two other similar kinase inhibitors, dasatinib and nilotinib, now underway. "If dasatinib or nilotinib can beat Gleevec in the response they elicit, they will offer patients even greater protection from relapse and possibly even better survival," he said. br>
Druker emphasized, however, that Gleevec and the other kinase inhibitors do not cure CML, they only control it. The researchers' findings showed that there remains a reservoir of aberrant cells that cause the disease to reappear if therapy is stopped. Thus, he said, he and his colleagues are working to understand those cells and how to eradicate them to ultimately cure the disease.

The outcome of the five-year study also offers lessons for physicians who are using Gleevec to treat other cancers, such as gastrointestinal stromal tumor, said Druker. "These findings tell us that we need to treat patients early in the course of the disease," he said. "In CML, there is the advantage that most patients get diagnosed at an early, chronic stage; whereas gastrointestinal stromal tumors are often diagnosed at a more advanced stage. Our results demonstrating Gleevec's high efficacy in CML tell us that in applying the drug to other cancers, we need to diagnose and treat patients earlier in the disease course.

"The lesson from Gleevec for cancer treatment is simple: if you understand what's driving the growth of the cancer and develop a specific drug to target that cause, you can obtain remarkable results," said Druker. "So, these findings should further encourage work toward greater understanding of all the molecular abnormalities in cancer and development of drugs that target those abnormalities."br>
###

Contact: Jennifer Michalowski
Howard Hughes Medical Institute
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 
 © 2002-2006

Keywords::

Contact Iconocast

Home Page